Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4291 Comments
1358 Likes
1
Karlette
Regular Reader
2 hours ago
This is frustrating, not gonna lie.
👍 61
Reply
2
Lizhet
Daily Reader
5 hours ago
I would watch a whole movie about this.
👍 177
Reply
3
Jarai
Active Contributor
1 day ago
My jaw is on the floor. 😮
👍 114
Reply
4
Maelyn
Community Member
1 day ago
Too late for me… sigh.
👍 95
Reply
5
Kanekoa
Legendary User
2 days ago
Indices are maintaining key levels, indicating equilibrium between buyers and sellers.
👍 18
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.